Mass Tort Data Intelligence
Real-time docket tracking, filing velocity, and litigation intelligence across 50 active mass tort dockets.
Meta Settles Mid-Trial — $18B Multi-State AG Deal Ends MDL 3047 Track 2 (47 States + DC + Territories)
Meta agreed to pay up to $18B over 10 years to resolve claims from a broad multi-state AG coalition alleging Instagram and Facebook were designed to addict minors and collected children's data in violation of COPPA. The deal — one of the largest AG settlements in U.S. history — was announced August 26, only 8 days into the Oakland federal trial that began August 18 before Judge Yvonne Gonzalez Rogers. $17.1B goes to the 29-state co-lead group that brought the original 2023 lawsuit (California AG Bonta co-lead); the balance covers the broader 47-state + DC + U.S. territories signatory pool (52 AGs total). Only New Mexico (already won ~$950M at trial) and Florida (AG rejected terms as too weak) are excluded. Beyond the cash, Meta agreed to sweeping platform changes: a 2-hour cumulative daily teen time limit across Facebook and Instagram (disable requires parental consent), blocked access midnight-6am, and muted notifications 8am-3pm on school days. Meta did not admit wrongdoing. META's market reaction was muted — +1.07% intraday to $576.14, adding ~$13.5B to market cap despite the $18B liability (net favorable given the trial's $1.4T theoretical statutory exposure was cleared). Jim Cramer called the market read 'ridiculous' and framed the deal as a 'big break' for Meta. Case-management ripple: the deal removes Meta's federal AG trial risk entirely; the ~2,400 remaining MDL 3047 personal-injury cases (individual plaintiffs, not AG plaintiffs) continue on separate tracks. The August 10 Ninth Circuit Section 230 ruling forced this trial to proceed — Meta chose settlement over verdict once the appellate escape was closed.
Defendant Market Impact
Verdict Breakdown
MDL 3047 Post-Settlement Landscape
Key Developments
$18B multi-state AG settlement announced Aug 26, 2026 — 8 days into Oakland trial
$17.1B to 29-state co-lead group; balance covers 47 states + DC + territories (52 AGs signed)
Only New Mexico (won ~$950M at trial) and Florida (rejected terms) excluded
10-year installment structure; no admission of wrongdoing
Sweeping platform changes: teen time limits, sleep-hour blackouts, school-hour notification mute
META +1.07% intraday — market read as clearing overhang, not distress; Cramer called it a 'big break'
~2,400 individual injury cases in MDL 3047 remain on separate tracks
Plaintiff Firm Rankings — Sep 6 – Sep 19, 2026
| # | Firm | City | Active Dockets | New | Leadership Status |
|---|---|---|---|---|---|
| 1 | Motley Rice LLC | Mt. Pleasant, SC | Social Media, AFFF, Talc | 45 | PSC — MDL 3047, MDL 2873 |
| 2 | Levin Papantonio Rafferty | Pensacola, FL | AFFF, Hair Relaxer, PowerPort | 38 | Co-Lead — MDL 2873 |
| 3 | Beasley Allen | Montgomery, AL | Paragard, Ozempic, Hair Relaxer | 32 | PSC — MDL 3094, MDL 2750 |
| 4 | Seeger Weiss LLP | New York, NY | Acetaminophen, FreeStyle Libre, Social Media | 30 | Co-Lead — MDL 3043 |
| 5 | Wisner Baum | Los Angeles, CA | Acetaminophen, Depo-Provera, Social Media | 28 | PSC — MDL 3043, MDL 3140 |
| 6 | Slater Slater Schulman | New York, NY | Uber, Lyft, Social Media | 25 | Lead — MDL 3084 |
| 7 | TorHoerman Law | Edwardsville, IL | Hair Relaxer, Paragard, Social Media | 22 | PSC — MDL 3060 |
| 8 | Weitz & Luxenberg | New York, NY | FreeStyle Libre, 1,4-Dioxane, Talc | 20 | PSC — MDL 2738 |
MDL Case Count Tracker — Sep 6 – Sep 19, 2026
50 dockets| Tort | MDL # | Total | New (Wk) | Trend | Key Development |
|---|---|---|---|---|---|
Tech | Pre-MDL | ~500+ | ~35 | FAST | State AG actions accelerating. Epic Games $520M FTC precedent. MDL formation expected 2026. |
Tech | 3047 | 10,000+ | ~30 | ACTIVE | Post-verdict momentum. Meta/Google appeal expected. Federal bellwether Jun 15 on track. |
Talc / J&JBorderline Consumer | 2738 | 67,200+ | ~45 | FILING | CA $950M verdict vacated Mar 17. Continued high-volume filing. |
Hair RelaxerOpen Consumer | 3060 | ~15,100 | ~25 | ACTIVE | BELLWETHER SELECTION: Judge Rowland selected 3 cases Apr 1. |
Chemical | 2873 | 15,250+ | ~40 | FILING | Steady high-volume intake. Motley Rice, Levin Papantonio active. |
Device | 2846 | 23,800+ | ~50 | FILING | Continued largest filing volume. |
Depo-ProveraOpen Pharma | 3140 | 3,490+ | ~40 | FAST | Expert deps completed Mar 20. Preemption motion under advisement. |
Pharma | 3092 | ~8,500 | ~5 | FLAT | Bellwether discovery continues. |
Ozempic / GLP-1Open Pharma | 3094 | 3,546+ | ~20 | ACTIVE | Entering critical Daubert/SJ phase. |
Bard PowerPortOpen Device | 3081 | 3,044+ | ~40 | ACTIVE | TRIAL IMMINENT: Cook bellwether Apr 21. |
Paragard IUDBorderline Device | 2750 | 3,600+ | ~25 | FILING | Beasley Allen, TorHoerman active. Mediation ongoing. |
Ozempic NAIONOpen Pharma | 3163 | 73+ | ~19 | FAST | Separate MDL created Dec 2025. NJ MCL active in parallel. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Seeger Weiss, Wisner Baum active. |
Tech | 3171 | ~170 | ~20 | FAST | Rapid intake continues. |
Tech | 3084 | 2,075+ | ~15 | FILING | Slater Slater Schulman active. |
Cartiva SCIOpen Device | 3172 | ~400 | ~10 | FILING | Mediation ongoing. Bellwether May 26. |
Dupixent CTCLOpen Pharma | 3180 | 18+ | ~5 | FAST | JPML MDL motion filed. Ruling expected soon. |
Nitrous OxideOpen Consumer | Pre-MDL | ~325 | ~25 | FAST | Pre-MDL. Multiple firms active. |
FreeStyle LibreOpen Device | Pre-MDL | ~215 | ~15 | FILING | Seeger Weiss, Weitz & Luxenberg active. |
1,4-DioxaneOpen Chemical | E.D.N.Y | 30+ | ~3 | FILING | Weitz & Luxenberg, Napoli Shkolnik active. |
ByHeart FormulaOpen Consumer | Pre-MDL | ~22 | ~4 | FILING | JPML Birmingham hearing Mar 26. Ruling imminent. |
Chemical | 2741 | 4,200+ | ~15 | ACTIVE | Bayer settlement ongoing. New cases still filing. |
Chemical | E.D.N.C. | 95,000+ | ~200 | FILING | PACT Act claims. Federal government defendant. |
Zantac / RanitidineClosed Pharma | 2924 | 2,100+ | ~2 | FLAT | Most claims dismissed. Science rulings unfavorable. |
ParaquatOpen Chemical | 3004 | 5,400+ | ~35 | FILING | Parkinson's disease link. Syngenta/Chevron defendants. |
Consumer | Pre-MDL | ~500 | ~20 | FAST | Emerging ovarian cancer claims separate from J&J. |
NEC Baby FormulaOpen Consumer | 3026 | 1,800+ | ~12 | ACTIVE | Abbott/Mead Johnson. Premature infant NEC claims. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Autism/ADHD link. Retailers as defendants. |
TepezzaOpen Pharma | Pre-MDL | ~200 | ~10 | FAST | Hearing loss side effect. Horizon Therapeutics. |
Philips CPAPOpen Device | 3014 | 750+ | ~8 | ACTIVE | Foam degradation. Cancer risk claims. |
ElmironBorderline Pharma | 2973 | 1,200+ | ~3 | FLAT | Vision damage. Settlement discussions ongoing. |
Exactech ImplantOpen Device | 3044 | 900+ | ~10 | FILING | Polyethylene insert failures. |
BelviqOpen Pharma | Pre-MDL | ~150 | ~8 | FAST | Cancer risk. Pulled from market 2020. |
Chemical | Pre-MDL | ~400 | ~15 | FAST | PFAS exposure. Emerging litigation. |
Toxic Baby FoodOpen Consumer | Pre-MDL | ~300 | ~10 | FILING | Heavy metals in baby food. Multiple defendants. |
FluoroquinoloneBorderline Pharma | Pre-MDL | ~250 | ~2 | FLAT | Cipro/Levaquin. Peripheral neuropathy. |
Proton Pump InhibitorsClosed Pharma | 2789 | 12,000+ | ~5 | FLAT | Nexium/Prilosec. Kidney damage. Mostly settled. |
IVC FilterClosed Device | 2641 | 3,800+ | ~3 | FLAT | Bard/Cook. Filter migration/fracture. |
RisperdalClosed Pharma | 2767 | 900+ | ~2 | FLAT | Gynecomastia. Most cases resolved. |
3M EarplugsClosed Device | 2885 | Settled | 0 | FLAT | $6B settlement complete. Monitoring ongoing. |
ValsartanClosed Pharma | 2875 | 1,400+ | ~3 | FLAT | NDMA contamination. Cancer claims. |
Consumer | 3038 | 4,500+ | ~15 | ACTIVE | Youth vaping. School district claims. |
Other | Pre-MDL | ~50 | ~3 | FAST | Antitrust. PGA merger implications. |
Tech | Pre-MDL | ~100 | ~5 | FILING | Driver-on-passenger assault claims. |
WeChat PrivacyOpen Tech | Pre-MDL | ~75 | ~4 | FAST | Data privacy violations. CCPA claims. |
Monsanto PCBOpen Chemical | 2342 | 2,500+ | ~10 | FILING | Environmental contamination. School claims. |
Consumer | 2738 | Part of Talc | ~20 | FILING | Subset of Talc MDL. |
Pharma | Pre-MDL | ~100 | ~5 | FAST | Autoimmune injury claims. Merck defendant. |
Metal-on-Metal HipClosed Device | 2244 | 4,000+ | ~2 | FLAT | DePuy/Stryker. Mostly resolved. |
Pharma | Pre-MDL | ~50 | ~3 | FAST | Immune-related organ failure. Merck defendant. |
Critical Dates — Next 60 Days
11 events| Date | Docket | Event | Investor Significance |
|---|---|---|---|
| Apr 1 | Hair Relaxer MDL 3060 | Bellwether case selection by Judge Rowland | Sets timeline for first federal trial; key valuation signal |
| Apr 7 | Social Media MDL 3047 | Expert report deadline — algorithmic amplification | Core liability theory; affects Daubert outcomes |
| Apr 10 | Social Media (NM State) | Google appeal filing deadline | Appellate strategy signals settlement posture |
| Apr 14 | Social Media JCCP 5255 | CA state coordination hearing | State-level consolidation affects case volume projections |
| Apr 14 | Social Media (NM State) | Post-trial motions deadline | JNOV ruling could modify $2.1B verdict |
| Apr 21 | Bard PowerPort MDL 3081 | Cook Medical bellwether trial begins | First trial in catheter port docket; high settlement leverage |
| May 5 | Depo-Provera MDL 3140 | Preemption motion ruling expected | Threshold legal issue — dismissal risk if granted |
| May 12 | Ozempic MDL 3094 | Daubert hearing — general causation experts | Make-or-break for GLP-1 litigation viability |
| May 26 | Cartiva SCI MDL 3172 | First bellwether trial | Initial trial outcome sets negotiation baseline |
| Jun 2 | Talc MDL 2738 | J&J 3rd prepackaged bankruptcy hearing | Could resolve or further delay 67K+ claims |
| Jun 15 | Social Media MDL 3047 | Federal bellwether trial begins | Landmark federal trial; massive settlement implications |
New Filings — Sep 6 – Sep 19, 2026
| Case | Defendant | Court | Theory | Lead Firm |
|---|---|---|---|---|
| Rodriguez v. Meta Platforms | Meta Platforms, Inc. | N.D. Cal. | Product liability — algorithmic addiction | Motley Rice LLC |
| Thompson v. Bard Medical | Bard Medical / BD | D. Ariz. | Device failure — catheter fracture | Levin Papantonio |
| Williams v. Pfizer Inc. | Pfizer Inc. | S.D.N.Y. | Failure to warn — Depo-Provera meningioma | Wisner Baum |
| Garcia v. Novo Nordisk | Novo Nordisk A/S | E.D. Pa. | GLP-1 gastroparesis / bowel obstruction | Beasley Allen |
| Davis v. Lyft, Inc. | Lyft, Inc. | N.D. Cal. | Negligent hiring — sexual assault | Slater Slater Schulman |
| Chen v. Abbott Labs | Abbott Laboratories | N.D. Ill. | Device defect — FreeStyle Libre burns | Seeger Weiss LLP |
Analyst Notes & Portfolio Strategy
Priority assessments, stage analysis, and portfolio positioning across active mass tort dockets.
Analyst Notes — Investor Outlook
Social Media Youth Addiction
Elevated PriorityThe NM verdict fundamentally shifts the litigation landscape. Federal bellwether on June 15 is the next major catalyst. Expect heightened settlement pressure on Meta/Google. Monitor appellate timeline closely — a sustained verdict dramatically increases portfolio exposure.
Talc / J&J
Bankruptcy WatchThird prepackaged bankruptcy attempt (June 2 hearing) remains the central variable. CA verdict vacation adds complexity. Resolution of 67K+ claims hinges on bankruptcy court approval of $8.9B trust proposal.
Hair Relaxer
Trial PreparationBellwether selections signal active progression. Three cases chosen April 1 will define trial strategy. L'Oreal, Revlon exposure significant. Watch for Daubert rulings on causation experts in coming weeks.
Depo-Provera
Elevated PriorityPreemption ruling (expected May 5) is threshold issue. If denied, rapid case growth likely accelerates. Pfizer exposure could be substantial given long market history and meningioma causation evidence.
Ozempic / GLP-1
Critical JunctureMay 12 Daubert hearing is make-or-break. Favorable ruling opens massive liability exposure for Novo Nordisk and Eli Lilly. Unfavorable ruling could significantly deflate docket. High-stakes binary outcome.
Bard PowerPort
Trial ImminentCook Medical bellwether (April 21) is the first catheter port trial. Outcome will set settlement benchmarks. BD/Bard cases to follow. Device failure evidence is strong — favorable plaintiff verdict expected.
Opportunities by Stage
Early signals. Pre-MDL formation. First-mover window.
Active investigation. Firms building inventory.
Meaningful case volume. Bellwethers approaching.
Multi-front mass tort. Settlement pressure.
The Diversified Core Portfolio
8 curated mass tort positions across 5 sectors and 4 stages.
Don't miss a ruling, verdict, or filing.
Every Monday: critical docket developments, filing velocity changes, bellwether outcomes, and portfolio signals — in one email.
Upload expert documents into the live docket board
Upload litigation reports, filings, or normalized JSON. Trusted docket facts become homepage overrides when they match a live MDL or tracked docket.